PHOTOCREO Michal Bednarek / Shutterstock.com
US Congress must exempt biopharmaceutical patents from PTAB review to ensure continued medical innovation, argues Peter Pitts of the Center for Medicine in the Public Interest.
The industry’s future, however, could be in jeopardy due to patent law changes across the Atlantic. British drug firms’ intellectual property faces an unprecedented threat from a US patent review board. The Patent Trial and Appeal Board (PTAB) has invalidated many legitimate patents.
In 2011, Congress passed the American Invents Act (AIA), which established the PTAB. Lawmakers hoped the PTAB would efficiently resolve disputes between patent owners and alleged infringers that challenge the legitimacy of certain patents. Congress gave the PTAB the power to invalidate the overly broad patents used by ‘patent trolls’.
You need a subscription to continue reading this content.
To access the full archive, digital magazines and special reports you will need to take out a paid subscription.
News stories up to a week old and feature articles on the day of publication are accessible with a BASIC FREE ACCOUNT.
If you have already subscribed please login.
If you have any technical issues please email tech support.
For access to the complete website, archive, and to receive print publications, choose '12 MONTH SUBSCRIPTION'. For a free, two-week trial with full access, select ‘TWO WEEK FREE TRIAL’; and for basic access to the latest news on the website and weekly email news alerts choose the 'BASIC FREE ACCOUNT' registration.
PTAB, AIA, patent, biopharma, Peter Pitts, Center for Medcine in the Public Interest,